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ABSTRAK
Latar belakang: antiretroviral drug-related liver injury (ARLI) adalah salah satu jenis hepatotoksisitas terkait 
obat yang disebabkan karena obat antiretroviral (ARV). Kejadian ARLI sering mengganggu kepatuhan berobat 
dan menyebabkan putus berobat pada pasien HIV. Beberapa penelitian telah dilakukan untuk mempelajari faktor 
predisposisi kejadian ARLI, di antaranya adalah penelitian tentang  indeks massa tubuh (IMT) dan cluster of 
differentiation 4 (CD4). Hubungan nilai IMT dan CD4 dengan kejadian ARLI masih menjadi kontroversi karena 
keluaran yang berbeda dari beberapa penelitian sebelumnya. Penelitian ini dilakukan untuk mengetahui hubungan 
IMT dan CD4 awal yang rendah sebagai faktor risiko kejadian ARLI pada pasien HIV. Metode: penelitian ini 
merupakan studi potong lintang pada 75 orang dengan HIV-AIDS (ODHA) yang mendapat terapi ARV dalam 
bentuk kombinasi dosis tetap (tenofovir, lamivudine, efavirenz) di Poliklinik Teratai Rumah Sakit Hasan Sadikin. 
Pemeriksaan Serum Glutamic Pyruvic Transaminase (SGPT) dilakukan sebelum ODHA memulai pengobatan ARV 
dan diulang pada bulan ke-6 pengobatan ARV. Hasil: tidak terdapat perbedaan bermakna proporsi hitung CD4 
awal yang rendah antara kelompok ARLI dan kelompok non-ARLI (p=0,155). Analisis bivariat menunjukkan bahwa 
terdapat perbedaan bermakna proporsi nilai IMT awal yang rendah antara kelompok ARLI dan kelompok non-
ARLI (p=0,001). Analisis multivariat dengan regresi logistik mendapatkan bahwa IMT <18,5 kg/m2 meningkatkan 
risiko 5,53 kali untuk terjadinya ARLI, sedangkan CD4 <200 sel/µl tidak meningkatkan risiko untuk terjadinya 
ARLI. Kesimpulan: nilai IMT awal yang rendah akan meningkatkan risiko terjadinya ARLI sedangkan hitung 
CD4 awal yang rendah tidak meningkatkan risiko terjadinya ARLI. Oleh karena itu, kami menyarankan bahwa 
pemeriksaan SGPT sebaiknya dilakukan secara rutin pada ODHA sebagai deteksi dini terjadinya ARLI, khususnya 
pada pasien dengan IMT rendah.
Kata kunci: antiretroviral drug-related liver injury (ARLI), indeks massa tubuh (IMT), cluster of 
differentiation 4 (CD4).
ABSTRACT
Background: antiretroviral drug-related liver injury (ARLI) is a drug-induced hepatotoxicity due to 
antiretroviral medication (ARV). It commonly disrupts compliance to treatment and causes treatment discontinuation 
in HIV-infected patients. Several studies have been conducted on predisposing factors for ARLI including studies 
on body mass index (BMI) and cluster of differentiation 4 (CD4). The association of BMI and CD4 with ARLI 
remains controversial as previous studies have demonstrated different outcomes. Our study was conducted to 
identify the association of low baseline BMI and CD4 cell count as risk factors for ARLI in HIV-infected patients. 
Methods: this is a cross-sectional study. Subjects were 75 patients with HIV-AIDS who received ARV therapy using 
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fixed-dose combination  (tenofovir, lamivudine, efavirenz) at the Teratai HIV outpatient clinic of Hasan Sadikin 
Hospital in Bandung city. Alanine aminotransferase (ALT) test was performed prior to starting ARV treatment and 
the test was repeated on the sixth month of therapy. Results: there was no significant difference on the proportion 
of low baseline CD4 count between ARLI and non-ARLI group (p=0.155). Bivariate analysis demonstrated that 
regarding the proportion of low baseline BMI, there was a significant difference between ARLI and non-ARLI group 
(p= 0.001). Multivariate analysis using logistic regression showed that BMI of <18.5 kg/m2 increased the risk 
for developing ARLI by 5.53 fold; while CD4 cell count of <200 cells/µL did not the risk. Conclusion: our study 
indicates that low baseline BMI may increase the risk for developing ARLI; while low baseline CD4 cell count 
does not; therefore, we suggest that ALT test should be performed on a routine basis among HIV-AIDS patients 
for early detection of ARLI, particularly in patients with low BMI.
Keywords: antiretroviral drug-related liver injury (ARLI), body mass index (BMI), cluster of differentiation 
4 (CD4).
INTRODUCTION
Antiretroviral drug-related liver injury 
(ARLI) is drug-induced liver injury caused by 
antiretroviral medication (ARV), particularly 
efavirenz and nevirapine.1 It is defined by 
elevated serum levels of liver enzymes and 
typically alanine aminotransferase (ALT) level 
is greater than aspartate aminotransferase (AST). 
Antiretroviral drug-related liver injury (ARLI) 
is a common cause of morbidity, mortality 
and treatment discontinuation in HIV-infected 
patients.1,2
Some risk factors for ARLI have been 
reported, which are female, viral hepatitis co-
infection, alcoholism, concurrent use of ARV 
with cotrimoxazole, low or high cluster of 
differentiation (CD4) count, antituberculosis 
drugs, low albumin serum, body mass index 
(BMI) and HIV-1 RNA load <20.000 copies/
ml.1,3-6 There are different outcomes in some 
studies about BMI and CD4 count as risk factors 
for ARLI.3-6
Sanne et al7 found that low BMI (<18.5 
kg/m2) is a risk factor for ARLI. In contrast, 
Chalermchai et al8 demonstrated that high BMI 
(≥ 23 kg/m2) is a risk factor for ARLI. Tseng et al3 
found that high baseline CD4 count (≥200 cell/
µl) is a risk factor for ARLI; while Hamzah et 
al4 found that low baseline CD4 cell count (<200 
cell/µl) is a risk factor for ARLI.
Low BMI causes altered drug absorption, 
distribution and excretion. Such conditions 
subsequently predispose HIV patients to 
hepatotoxicity.9 Cluster differentiation acts 
as a coordinator in various immune function. 
The loss of this function causes progressive 
disturbance in immune response.10 It results in 
increased risk of having opportunistic infection 
on liver, which induces hepatotoxicity.4
All kinds of ARV medication can cause 
ARLI, especially nevirapine and protease 
inhibitors.1 Most of HIV patients in Bandung 
have been receiving ARV medication using the 
fixed-dose combination (tenofovir, lamivudine, 
efavirenz) and they have lost more than 10 % of 
their weight as well as having low baseline CD4 
cell count. There has been no data regarding the 
association of low baseline BMI and CD4 cell 
count with ARLI in HIV patients in Bandung 
city, West Java. The aim of our study was to 
identify the association of low baseline BMI and 
CD4 cell count with their roles as risk factors 
for ARLI.
METHODS
The present  s tudy was  a  c l in ica l 
epidemiological study using cross-sectional 
design. The study was conducted starting from 
September to November 2017. It included 
subjects of >18 year-old HIV patients who 
received ARV treatment using fixed dose 
combination (tenofovir, lamivudine, efavirenz) 
at the Teratai HIV Outpatient Clinic in Hasan 
Sadikin Hospital. Subjects with ALT ≥1.25x 
the upper limit of normal (ULN) ALT levels 
before receiving ARV treatment, patients 
with pregnancy, concurrent use of antifungal 
treatment (fluconazole), TB-HIV co-infection or 
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using antituberculosis medicine were excluded. 
The exclusion was performed to minimize 
any bias that might cause elevated ALT level. 
Ethical approval was obtained from the Ethics 
Committee of Faculty of Medicine, Padjadjaran 
University/Hasan Sadikin Hospital, Bandung on 
September 11, 2017 with a reference number of 
LB.04.01/A05/EC/271/IX/2017.
In the present study, randomized consecutive 
sampling was utilized with minimum sample 
size of 68 subjects. History taking, physical 
examination and laboratory tests examination 
were carried out at the Teratai Outpatient Clinic. 
BMI, CD4 cell count and ALT baseline data 
were documented before HIV patients started 
their ARV regimens. The second ALT test was 
taken within six months after the subjects had 
started their ARV treatment. The sixth month 
was selected as the cut-off time to re-asses ALT 
level considering that Chalasani et al11 had 
demonstrated that the event of drug-induced 
liver injury  usually occurs within the first 
six months after a patient starting any new 
medication. Subjects with an increase of ALT 
level <1.25x the ULN were categorized into the 
non-ARLI group; while subjects with increased 
ALT level ≥1.25x the ULN were categorized into 
the ARLI group.
Human Immunodeficiency Virus (HIV) 
infection was confirmed by reactive anti-HIV 
test. By dividing body weight (kg) with the 
square of height (m2), we got the BMI. Low BMI 
was defined as BMI <18.5 kg/m2.4,7 Low CD4 
cell count was defined as CD4 count of <200 
cells/µl.4 Antiretroviral drug-related liver injury 
(ARLI) was defined  when there was an increased 
ALT level ≥1.25x the upper limit normal (ULN) 
on the sixth month of ARV therapy.1 The ULN 
for ALT in our study was 40 IU/ml.
Data were analyzed using bivariate analysis 
with chi square test or Fisher’s exact test 
when the criteria for chi square were not 
fulfilled. It was then continued by multivariate 
analysis using logistic regression. The evaluated 
parameters were expressed in confidence interval 
(CI), probability (p value) and odd ratio (OR). 
All statistical tests were evaluated using SPSS 
software program version 25.0.
RESULTS
Seventy-five subjects were selected including 
34 subjects in ARLI group and 41 subjects 
in non-ARLI group. Baseline characteristics 
such as age, sex, baseline CD4 cell count, 
baseline BMI, viral hepatitis B coinfection and 
cotrimoxazole usage can be seen in Table 1. The 
average age of our subjects was 32 years old. 
There were 61 (81.3%) male and 14 (18.7%) 
female subjects. The CD4 cell count ranged 
between 6 and 554 cells/µL (with a median of 
210 cells/µL). There were 33 (44%) subjects 
with low baseline CD4 cell count (< 200 cells/µl) 
and there were 42 (56%) subjects with baseline 
CD4 cell count ≥200 cells/µl. The average 
BMI of our subjects before starting their ARV 
Table 1. Baseline characteristics with ARLI
Characteristics Total (n = 75) ARLI (n=34) Non-ARLI (n=41) p value
Age (years old), Mean (SD) 32 (9) 33 (7) 30 (10) 0.148a
Sex, n (%)
 - Male 61 (81.3) 29 (85.3) 32 (78.0) 0.423b
 - Female 14 (18.7) 5 (14.7) 9 (22.0)
Viral hepatitis B coinfection, n (%) 6 (8.0) 4 (11.8) 2 (4.9) 0.401c
Cotrimoxazole prophylaxis, n (%) 32 (42.7)  16 (47.1) 16 (39.0) 0.484b
CD4 (cells/µl), n (%)
 - CD4 < 200 33 (44.0) 18 (52.9) 15 (36.6) 0.155b
 - CD4 ≥ 200 42 (56.0) 16 (47.1) 26 (63.4)
BMI (kg/m2), n (%)
 - BMI < 18.5 31 (41.3) 21 (61.8) 10 (24.4) 0.001b*
 - BMI ≥ 18.5 44 (58.7) 13 (38.2) 31 (75.6)
Abbreviations: SD=standard deviation, n=amount, %=percentage, at test, bChi Square, cFisher Exact
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therapy was 19.5 kg/m2. There were 31 (41.3%) 
subjects with low baseline BMI (<18.5 kg/m2) 
and 44 (58.7%) subjects with BMI ≥ 18.5 kg/m2. 
There were 6 (8%) subjects with viral hepatitis 
B coinfection and 32 (42.7%) subjects were 
using cotrimoxazole coincidentally with ARV. 
There were no significant differences in age, sex, 
viral hepatitis B coinfection and cotrimoxazole 
prophylaxis treatment between ARLI group and 
non-ARLI group (p>0.05).
There were 34 subjects with ARLI including 
27 (79.4%) subjects experiencing ARLI grade 
1, 4 (11.8%) subjects with ARLI grade 2, 2 
(5.9%) subjects experiencing ARLI grade 3 and 
1 subject (2.9%) with ARLI grade 4.
Bivariate analysis on baseline CD4 cell 
count between ARLI and non-ARLI group was 
performed using chi-square test. There were 
18 (52.9%) subjects with low baseline CD4 
cell count (CD4 <200 cells/µl) and 16 (47.1%) 
subjects with CD4 cell count ≥ 200 cells/µl in 
ARLI group. There were 41 subjects non-ARLI 
group including 15 (36.6%) subjects with low 
baseline CD4 count (<200 cells/µl) and 26 
(63.4%) subjects with CD4 cell count of ≥ 200 
cells/µl. There was no significant statistical 
difference between both groups (p=0.155).
Bivariate analysis on baseline BMI between 
ARLI and non-ARLI was also performed using 
chi-square test. There were 21 (61.8%) subjects 
with baseline BMI <18.5 kg/m2 and 13 (38.2%) 
subjects with baseline BMI ≥18.5 kg/m2 in ARLI 
group. There were 41 subjects in non-ARLI 
group and there were 10 (24.4%) subjects with 
baseline BMI <18.5 kg/m2 and 31 (75.6%) 
subjects with baseline BMI ≥18.5 kg/m2. 
Statistically, there was a significant difference 
(p=0.001) between both groups.
Body mass index <18.5 kg/m2 increased 
the risk for ARLI 5.53 folds; however, the CD4 
cell count of <200 cells/µl did not increase the 
risk for ARLI. All subjects received fixed-dose 
combination ARV treatment, which consisted of 
tenofovir, lamivudine and efavirenz.
DISCUSSION
The results showed that there was no 
significant difference in low baseline CD4 cell 
count proportion between ARLI and non-ARLI 
group (p=0.155). Multivariate analysis using 
logistic regression showed that low baseline 
CD4 cell count (<200 cells/µl) did not increase 
the risk for ARLI (p=0.754). Chaponda et al12 and 
Nunez13 found that HIV patients with baseline 
CD4 > 250 cell/µl suffer ARLI more often. This 
may be caused by hypersensitivity reaction. 
Hypersensitivity reaction in ARLI is often caused 
by nevirapine (NVP).1,12,13 Nevirapine induces 
hepatotoxicity more frequently than evafirenz 
(EFV). Nevirapine-based hepatotoxicity comes 
in two different onsets. The first one can be found 
within six weeks after the initiation of NVP. The 
other one may occur within 2 to 3 months after 
the initiation of NVP.12,14
Although the mechanisms of hepatotoxicity 
are not clear, recent evidence has pointed 
to a specific mitochondrial action of EFV 
accompanied by the induction of an endoplasmic 
reticulum stress or unfolded protein response 
in human hepatocytes. Endoplasmic reticulum 
stress, which is triggered by EFV, can be 
exacerbated in any settings that may futher 
compromise liver function including viral 
hepatitis and drug or alcohol abuse.15
Cluster differentiation produces cytokines 
such as IL-5, granzyme and eotaxin, which play 
big roles in eosinophil growth and differentiation. 
High levels of CD4 cells will produce more 
eosinophils. Eosinophil has a significant role in 
allergic reaction and hypersensitivity.12
Our study showed that there was a significant 
difference regarding the proportion of low BMI 
Table 2. The association of baseline CD4 cell count and BMI with ARLI
Coeficient B SE p-value Odd Ratio (95% CI)
BMI < 18.5 kg/m2 1.710 0.602 0.005*  5.530 (1.699 – 17.999)
CD4 < 200 cells/µl -0.188 0.599 0.754 0.829 (0.259 – 2.681)
Constant -0.828 0.354 0.020
Multivariate analysis logistic regression, *significant if p<0.05; dependent variable: ARLI
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between ARLI and non-ARLI group (p=0.001). 
Multivariate analysis using logistic regression 
showed that there was a correlation between 
low baseline BMI and ARLI (p=0.005). Low 
BMI (<18.5 kg/m2) increases the risk for ARLI 
as many as 5.53 folds. The result was consistent 
with a study by Sanne et al7, which found 65% 
ARLI proportion in subjects with baseline BMI 
<18.5 kg/m2. Hamza et al4 in Nigeria also found 
that baseline BMI <18.5 kg/m2 had a significant 
correlation with ARLI.
Malnutrition (BMI <18.5 kg/m2) results 
in changes in drug metabolisms starting from 
absorption, distribution to excretion. The 
disruption of gut wall function in patients with 
malnutrition causes drug malabsorption.9 Gut 
wall plays an essential role in drug absorption. 
Enterocytes in gut wall contain many types 
of enzymes such as cytochrome P450 3A4 
(CYP3A4), peptide transporter 1 (PEPT1) 
and P-glycoprotein (P-gp). Cytochrome P450 
3A4 (CYP3A4) is a dominant enzyme in drug 
absorption and metabolism.16 In malnutrition, the 
amount and function of those enzymes attenuate 
resulting in drug malabsorption.9
Reduced lipid tissue and hypoalbuminemia in 
malnutrition cause disruption in drug distribution. 
Malnutrition may result in reduced amount and 
function of cytochrome in the liver. Cytochrome 
plays a role in the first phase of drug metabolism. 
Reduced cytochrome enzyme may cause increased 
drug level and delayed formation of  drug 
metabolites, which may lead to hepatotoxicity.9
One limitation of our study was our cross-
sectional design; therefore, we could not study 
ARLI incidence with a time frame of more than 
six month after the subjects has initiated their 
ARV treatment. Moreover, other factors such 
as ARV regimen, other hepatic diseases (other 
than viral hepatitis B), alcohol consumption, 
serum albumin and other medication (other than 
antituberculosis and fluconazole) were also not 
in our study. There was also cost limitation in our 
study that prevented us to assess the association 
between viral hepatitis C co-infection and HIV.
CONCLUSION
Our study concludes that low baseline 
BMI is a risk factor for ARLI. There are no 
significant differences in age, sex, viral hepatitis 
B co-infection and cotrimoxazole prophylaxis 
between ARLI group and non-ARLI group. 
There is a significant difference of low BMI 
proportion between ARLI and non-ARLI group. 
Low BMI (<18.5 kg/m2) increases the risk for 
ARLI 5.53 folds; while CD4 cell count <200 
cells/µl does not increase the risk for ARLI.
We suggest a routine ALT test every six 
months after ARV treatment is initiated for HIV 
patients with malnutrition (BMI <18.5 kg/m2) 
for early detection of ARLI.
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